Seeking Alpha

Auxilium Pharmaceuticals (AUXL +0.3%) and strategic partner BioSpecifics (BSTC +1.3%) both move...

Auxilium Pharmaceuticals (AUXL +0.3%) and strategic partner BioSpecifics (BSTC +1.3%) both move up after The Journal of Urology publishes its Impress Study, a Phase 3 trial of Xiaflex for the treatment of Peyronie's disease, which is an excess of inelastic collagen causing penile curvature deformity. AUXL previously announced positive top-line efficacy and safety results of the studies' co-primary endpoints, and based on the new results, has submitted a supplemental Biologics License Application (sBLA) to the FDA.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|